Marker Therapeutics Stock Current Valuation
| MRKR Stock | USD 3.89 0.09 2.26% |
Valuation analysis of Marker Therapeutics helps investors to measure Marker Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of 12/12/2024, Enterprise Value is likely to grow to about 27.1 M, while Enterprise Value Over EBITDA is likely to drop (2.97). Fundamental drivers impacting Marker Therapeutics' valuation include:
Price Book 4.6596 | Enterprise Value 16.6 M | Enterprise Value Ebitda (0.22) | Price Sales 9.3127 | Enterprise Value Revenue 3.4122 |
Undervalued
Today
Please note that Marker Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of Marker Therapeutics is based on 3 months time horizon. Increasing Marker Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Marker stock is determined by what a typical buyer is willing to pay for full or partial control of Marker Therapeutics. Since Marker Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Marker Stock. However, Marker Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 3.89 | Real 12.72 | Target 40.0 | Hype 3.81 | Naive 4.51 |
The intrinsic value of Marker Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Marker Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Marker Therapeutics helps investors to forecast how Marker stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Marker Therapeutics more accurately as focusing exclusively on Marker Therapeutics' fundamentals will not take into account other important factors: Marker Therapeutics Company Current Valuation Analysis
Marker Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Marker Therapeutics Current Valuation | 16.59 M |
Most of Marker Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Marker Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Marker Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Marker Therapeutics is extremely important. It helps to project a fair market value of Marker Stock properly, considering its historical fundamentals such as Current Valuation. Since Marker Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Marker Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Marker Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Marker Current Valuation Historical Pattern
Today, most investors in Marker Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Marker Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Marker Therapeutics current valuation as a starting point in their analysis.
Marker Therapeutics Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Marker Therapeutics has a Current Valuation of 16.59 M. This is 99.88% lower than that of the Biotechnology sector and 99.64% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.9% higher than that of the company.
Marker Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Marker Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Marker Therapeutics could also be used in its relative valuation, which is a method of valuing Marker Therapeutics by comparing valuation metrics of similar companies.Marker Therapeutics is currently under evaluation in current valuation category among its peers.
Marker Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Marker Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Marker Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Marker Fundamentals
| Return On Equity | -0.72 | ||||
| Return On Asset | -0.41 | ||||
| Profit Margin | (2.78) % | ||||
| Operating Margin | (1.97) % | ||||
| Current Valuation | 16.59 M | ||||
| Shares Outstanding | 8.92 M | ||||
| Shares Owned By Insiders | 12.19 % | ||||
| Shares Owned By Institutions | 22.44 % | ||||
| Number Of Shares Shorted | 50.09 K | ||||
| Price To Earning | (9.39) X | ||||
| Price To Book | 4.66 X | ||||
| Price To Sales | 9.31 X | ||||
| Revenue | 3.31 M | ||||
| Gross Profit | (17.13 M) | ||||
| EBITDA | (11.79 M) | ||||
| Net Income | (14.05 M) | ||||
| Cash And Equivalents | 18.08 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 3.07 M | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 1.99 X | ||||
| Book Value Per Share | 1.58 X | ||||
| Cash Flow From Operations | (16.44 M) | ||||
| Short Ratio | 1.55 X | ||||
| Earnings Per Share | (1.07) X | ||||
| Target Price | 19.0 | ||||
| Beta | 1.49 | ||||
| Market Capitalization | 34.71 M | ||||
| Total Asset | 17.13 M | ||||
| Retained Earnings | (436.29 M) | ||||
| Working Capital | 14.05 M | ||||
| Current Asset | 6.85 M | ||||
| Current Liabilities | 5.93 M | ||||
| Net Asset | 17.13 M |
About Marker Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marker Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marker Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marker Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Marker Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Marker Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Marker Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Marker Stock
| 0.57 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.48 | SLS | Sellas Life Sciences | PairCorr |
| 0.32 | ERNA | Eterna Therapeutics | PairCorr |
| 0.31 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
The ability to find closely correlated positions to Marker Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Marker Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Marker Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Marker Therapeutics to buy it.
The correlation of Marker Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Marker Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Marker Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Marker Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Marker Stock Analysis
When running Marker Therapeutics' price analysis, check to measure Marker Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marker Therapeutics is operating at the current time. Most of Marker Therapeutics' value examination focuses on studying past and present price action to predict the probability of Marker Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marker Therapeutics' price. Additionally, you may evaluate how the addition of Marker Therapeutics to your portfolios can decrease your overall portfolio volatility.